Peer-influenced content. Sources you trust. No registration required. This is HCN.

Gastroenterology AdvisorAI Detection System Has Higher Adenomas Per Colonoscopy Rate

Enhancing Colonoscopy Efficacy: The AI Revolution in Adenoma Detection

In a significant stride toward improving colonoscopy quality, a recent study published in the American Journal of Gastroenterology reveals that an artificial intelligence (AI) system, CADEYETM, substantially outperforms conventional colonoscopy in detecting adenomas. This groundbreaking research underscores the potential of AI to enhance diagnostic accuracy in gastroenterology, offering a promising avenue for early detection and prevention of colorectal cancer.

Key Points:

  • The AI detection system CADEYETM demonstrated a 17% higher adenomas per colonoscopy (APC) rate compared to conventional colonoscopy.
  • The study, a multicenter, prospective, randomized controlled trial, involved 1,857 patients undergoing colonoscopy, comparing AI-assisted procedures to traditional methods.
  • The primary metric, APC, significantly favored AI-assisted colonoscopy, with a rate of 0.990 versus 0.849 for conventional methods.
  • AI colonoscopy detected more total polyps and serrated lesions per procedure than conventional colonoscopy, although rates for sessile serrated lesions and neoplasia were similar between the two.
  • The adenoma detection rate (ADR), a crucial indicator of colonoscopy effectiveness, was comparable between AI-assisted and conventional colonoscopies, reinforcing the AI system’s noninferiority.
  • Subgroup analysis revealed that the AI system particularly excelled in surveillance colonoscopy, offering superior APC rates compared to screening colonoscopies.
  • The implementation of AI did not significantly extend the withdrawal time during colonoscopy, indicating an efficient integration into current practices.

“[A] novel real-time AI detection CADEYETM system showed higher detection of adenoma per colonoscopy compared to conventional high-definition colonoscopy without substantial increase in the withdrawal time. This data supports the use of CADEYETM for improving colonoscopy quality.”
– The Researchers

More in Colorectal Cancer (CRC)

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form